Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study.

Date publication

janvier 2015

Journal

PloS one

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme

Tous les auteurs :
Leray E, Vukusic S, Debouverie M, Clanet M, Brochet B, de Sèze J, Zéphir H, Defer G, Lebrun-Frenay C, Moreau T, Clavelou P, Pelletier J, Berger E, Cabre P, Camdessanché JP, Kalson-Ray S, Confavreux C, Edan G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26148099

Résumé

Recent studies in multiple sclerosis (MS) showed longer survival times from clinical onset than older hospital-based series. However estimated median time ranges widely, from 24 to 45 years, which makes huge difference for patients as this neurological disease mainly starts around age 20 to 40. Precise and up-to-date reference data about mortality in MS are crucial for patients and neurologists, but unavailable yet in France.

Mots clés

Adult, Aged, Female, Follow-Up Studies, France, epidemiology, Humans, Life Expectancy, Male, Middle Aged, Multiple Sclerosis, mortality, Registries, Retrospective Studies, Sex Factors

Référence

PLoS ONE. 2015 ;10(7):e0132033